

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

INSIDE INFORMATION

SHAREHOLDER DIVIDEND DISTRIBUTION AND RETURN PLAN FOR THE THREE FINANCIAL YEARS ENDING 31 DECEMBER 2028

This announcement is made by **AK Medical Holdings Limited** (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on the basis of its confidence in the future performance and long-term development prospects of the Group and the Group’s sound cash flow position, in order to further enhance the returns to the shareholders of the Company (the “**Shareholders**”), the Board has resolved to adopt a new dividend policy (the “**Shareholder Dividend Distribution and Return Plan**”), pursuant to which:

- (a) for the financial year ending 31 December 2026, the annual dividend payout ratio will be increased to not less than 55% of the profit for the year attributable to equity shareholders of the Company as set out in the Group’s audited consolidated financial statements for that financial year; and
- (b) for each of the financial years ending 31 December 2027 and 31 December 2028, the annual dividend payout ratio will be increased to not less than 60% of the profit for the year attributable to equity shareholders of the Company as set out in the Group’s audited consolidated financial statements for the relevant financial year.

The Company intends to fund the Shareholder Dividend Distribution and Return Plan by the internal resources of the Group and the Company does not expect that the implementation of the Shareholder Dividend Distribution and Return Plan will have any material adverse impact on the working capital position of the Group.

The Board believes that the Group's sound cash flow position provides support for the increase in the dividend payout ratio. After full consideration of the funding required for daily operations, capital expenditure and future business development, the Board considers that this enhancement in dividend policy will help improve capital utilization efficiency and enable the Shareholders to share more fully in the Group's operating results while supporting the Group's sustained development. The Company places great importance on providing the Shareholders with sustainable and stable returns. Such increase in the dividend payout ratio demonstrates the Board's confidence in the Group's future profitability and cash-generating capabilities, and also underscores the Company's commitment to enhancing long-term value for the Shareholders.

Shareholders and potential investors of the Company are advised that the implementation of the Shareholder Dividend Distribution and Return Plan is subject to the sole discretion of the Board from time to time. Any dividend declarations will be made by reference to, among other considerations, the Group's operating performance and cash flow position.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, 9 September 2026

As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Dr. Wang David Guowei as non-executive Director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Dr. Gao Wei as independent non-executive Directors.